TITLE

Plan B One-Step Update

PUB. DATE
March 2012
SOURCE
MPR - Pharmacist's Edition;Spring2012, Vol. 6 Issue 1, pA:7
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article focuses on the announcement from the U.S. Food and Drug Administration (FDA) regarding the continued availability of Plan B One-Step, a levonorgestrel tablet, from Teva Pharmaceutical Industries Ltd. by prescription only for females less than 17 years old with childbearing potentials.
ACCESSION #
73344570

 

Related Articles

  • Idled Pharma Plant Re-Opens One Year Later. Van Milligen, Dennis // Processing (08968659);May2011, Vol. 24 Issue 5, p4 

    The article reports that the Teva Pharmaceutical Industries' plant in Irvine, California, has reopened after it was temporarily shutdown when the Food and Drug Administration found it had failed to test for endotoxin in raw materials used in making propofol.

  • Generic Cipro on horizon.  // Drug Store News;1/21/2002, Vol. 24 Issue 1, p37 

    Reports on the tentative approval received by Teva Pharmaceuticals from the United States Food and Drug Administration to market the antibiotic ciprofloxacin.

  • Tentative approval for generic Capozide.  // Drug Store News;8/18/97, Vol. 19 Issue 13, pCP32 

    Discloses that Teva Pharmaceutical Industries Ltd. has received tentative approval from the US Food and Drug Administration to manufacture and market captopril and hydrochlorothiazide tablets, a drug indicated for hypertension.

  • Treanda delivery device incompatibility update.  // Reactions Weekly;Sep2015, Vol. 1569 Issue 1, p9 

    The article informs that the U.S. Food & Drug Administration has published a list of specific closed system transfer devices, syringes, vial adapters and disposable gloves which has been tested by the company Teva Pharmaceuticals and compatible with Treanda Injection solution.

  • FDA GRANTS TENTATIVE APPROVAL OF SICOR'S FLUMAZENIL I.  // Worldwide Biotech;Jun2004, Vol. 16 Issue 6, p1 

    Reports on the decision of the U.S. Food and Drug Administration to temporarily approve of an abbreviated new drug application for the Flumazenil Injection from Teva Pharmaceutical Industries Ltd. of Jerusalem, Israel. Use of the Flumazenil Injection; Annual sales performance of the product;...

  • Teva wins FDA approval for generic schizophrenia drug.  // PharmaWatch: CNS;Mar2009, Vol. 8 Issue 3, p11 

    The article reports on the approval of the Teva's generic schizophrenia drug from U.S. Food and Drug Administration. It states that the company was granted to market its generic version of Janssen's antipsychotic agent Risperdal oral solution. It adds that Teva was given a 180-day period to...

  • Parkinson's Disease Update.  // PharmaWatch: CNS;Apr2010, Vol. 9 Issue 4, p7 

    The article offers an update on the treatment of Parkinson's disease in the U.S. The Food and Drug Administration (FDA) has given approval on Boehringer Ingelheim Parkinson's drug Mirapex ER extended release tablets and made Abbreviated New Drug Application approval for the drug ropinirole...

  • Teva: GSK's latest headache.  // PharmaWatch: CNS;Jan2007, Vol. 6 Issue 1, p16 

    The article focuses on the tentative approval received by Teva Pharmaceutical Industries Ltd. for sumatriptan succinate anti-migraine drug from the U.S. Food and Drug Administration. The firm has become the latest addition to companies that aim to challenge the Imitrex drug of GlaxoSmithKline....

  • Pharma: Other News To Note.  // BioWorld Today;4/6/2012, Vol. 23 Issue 67, p7 

    The article reports on the 180-day exclusivity granted by the U.S. Food and Drug Administration (FDA) to a drug application filed by Teva Pharmaceutical Industries Ltd. for its wakefulness drug Provigil.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics